

# Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence



World Health  
Organization



# Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence

WHO Library Cataloguing-in-Publication Data

**Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence.**

1.Opioid-related disorders - drug therapy. 2.Opioid-related disorders - psychology. 3.Substance abuse - prevention and control. 4.Guidelines. I.World Health Organization. Dept. of Mental Health and Substance Abuse.

ISBN 978 92 4 154754 3

(NLM classification: WM 284)

© World Health Organization 2009

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Book design by Zando Escultura

Printed in

# Contents

<b>Acknowledgements</b> .....	iv
<b>Abbreviations and acronyms</b> .....	ix
<b>Executive summary</b> .....	x
Summary of recommendations.....	xiv
<b>1 Scope and purpose</b> .....	1
<b>2 Method of formulating recommendations</b> .....	3
2.1 Conventions for reporting clinical trial data.....	4
<b>3 Background</b> .....	5
3.1 Opioid dependence.....	5
3.2 Neurobiological aspects of opioid dependence.....	5
3.3 Epidemiology of illicit opioid use and dependence.....	6
3.4 Harms associated with opioid use.....	6
3.5 Economic consequences of opioid use.....	6
3.6 Natural history of opioid dependence.....	6
3.7 Opioid dependence as a medical condition.....	6
3.8 Treatment of opioid dependence.....	7
3.8.1 Management of opioid withdrawal.....	7
3.8.2 Agonist maintenance treatment.....	7
3.8.4 Psychosocial assistance.....	7
<b>4 Guidelines for health systems at national and subnational levels</b> .....	8
4.1 International regulations.....	8
4.2 Opioid dependence as a health-care issue.....	8
4.3 National treatment policy.....	8
4.4 Ethical issues.....	9
4.4.1 Compulsory and coerced treatment.....	9
4.4.2 Central registration of patients.....	10
4.5 Funding.....	10
4.6 Coverage.....	11
4.6.1 Primary care.....	11
4.6.2 Prisons.....	12
4.7 What treatments should be available?.....	12
4.8 Supervision of dosing for methadone and buprenorphine maintenance.....	13
<b>5 Programme level guidelines – for programme managers and clinical leaders</b> .....	14
5.1 Clinical governance.....	14
5.2 Ethical principles and consent.....	14
5.3 Staff and training.....	15
5.3.1 Medical staff.....	15
5.3.2 Pharmacy staff.....	15
5.3.3 Psychosocial support staff.....	16
5.4 Clinical records.....	16

5.5	Medication safety.....	16
5.6	Treatment provision.....	17
5.6.1	Clinical guidelines.....	17
5.6.2	Treatment policies.....	17
5.6.3	Involuntary discharge and other forms of limit setting.....	17
5.6.4	Individual treatment plans.....	18
5.6.5	Range of services to be provided.....	19
5.6.6	Treatment of comorbid conditions.....	19
5.6.7	Psychosocial and psychiatric support.....	19
5.6.8	TB, hepatitis and HIV.....	20
5.6.9	Hepatitis B vaccination.....	21
5.7	Treatment evaluation.....	21
<b>6</b>	<b>Patient level guidelines – for clinicians.....</b>	<b>23</b>
6.1	Diagnosis and assessment of opioid dependence.....	23
6.1.1	urine drug screening.....	24
6.1.2	Testing for infectious diseases.....	24
6.1.3	Identifying the patient.....	24
6.1.4	Completing the assessment.....	24
6.1.4	Diagnostic criteria.....	25
6.1.5	Making the diagnosis.....	25
6.2	Choice of treatment approach.....	26
6.3	Opioid agonist maintenance treatment.....	29
6.3.1	Indications for opioid agonist maintenance treatment.....	29
6.3.2	Choice of agonist maintenance treatment.....	29
6.3.3	Initial doses of opioid agonist maintenance treatment.....	32
6.3.4	Fixed or flexible dosing in agonist maintenance treatment.....	32
6.3.5	Maintenance doses of methadone.....	33
6.3.6	Maintenance doses of buprenorphine.....	34
6.3.7	Supervision of dosing in opioid agonist maintenance treatment.....	35
6.3.8	Optimal duration of opioid agonist treatment.....	36
6.3.9	Use of psychosocial interventions in maintenance treatment.....	37
6.4	Management of opioid withdrawal.....	38
6.4.1	Signs, severity and treatment principles.....	38
6.4.2	Assessment of opioid withdrawal.....	38
6.4.3	Choice of treatments for assisting withdrawal from opioids.....	39
6.4.4	Accelerated withdrawal management techniques.....	41
6.4.5	Treatment setting for opioid withdrawal.....	43
6.4.8	Psychosocial assistance in addition to pharmacological assistance for opioid withdrawal.....	44
6.5	Opioid antagonist (naltrexone) treatment.....	45
6.5.1	Indications for opioid antagonist therapy.....	45
6.5.2	Indications for naltrexone therapy.....	46
6.6	Psychosocial interventions.....	47
6.6.1	Psychological interventions.....	47
6.6.2	Social interventions.....	48
6.6.3	Provision of psychosocial support.....	48
6.7	Treatment of overdose.....	48

6.8	Special considerations for specific groups and settings.....	49
6.8.1	Patients with HIV/AIDS, hepatitis and TB.....	49
6.8.2	Adolescents.....	49
6.8.3	Women.....	51
6.8.4	Pregnancy and breastfeeding.....	51
6.8.5	Opium users.....	52
6.8.6	Driving and operating machinery.....	52
6.8.7	Psychiatric comorbidity with opioid dependence.....	52
6.8.8	Polysubstance dependence.....	52
6.9	Management of pain in patients with opioid dependence.....	53
6.9.1	Acute pain.....	53
6.9.2	Chronic pain.....	54
	Annex 1 Evidence profiles.....	55
	Annex 2 Dispensing, dosing and prescriptions.....	70
	Annex 3 ICD-10 codes for conditions covered in these guidelines.....	71
	Annex 4 Pharmacology of medicines available for the treatment of opioid dependence.....	72
	Annex 5 Drug interactions involving methadone and buprenorphine.....	74
	Annex 6 Alternatives for the treatment of opioid dependence not included in the current guidelines.....	77
	Annex 7 Methadone and buprenorphine and international drug control conventions.....	78
	Annex 8 Priorities for research.....	82
	Annex 9 Background papers prepared for technical expert meetings to inform guideline development.....	84
	Annex 10 Opioid withdrawal scales.....	85
	Annex 11 Summary of characteristics of selected psychoactive substances.....	89
	Annex 12 Prescribing guidelines.....	90
	Annex 13 Glossary.....	93
	<b>References.....</b>	<b>96</b>

# Acknowledgements

These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and

in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project.

## GUIDELINES DEVELOPMENT GROUP

### Marina Davoli

Coordinating Editor  
Cochrane Review Group on Drugs and Alcohol  
Department of Epidemiology  
Osservatorio Epidemiologico Regione Lazio  
Roma  
Italy

### Michael Farrell

Reader/Consultant Psychiatrist  
National Addiction Centre  
Institute of Psychiatry and the Maudsley Hospital  
London  
United Kingdom

### David Fiellin

Associate Professor of Medicine  
Yale University School of Medicine  
United States of America

### Li Jianhua

Deputy Director  
Yunnan Institute for Drug Abuse  
China

### Ratna Mardiaty

Psychiatrist  
Directorate General for Medical Care  
Jakarta  
Indonesia

### Fred Owiti

Consultant Psychiatrist  
Arrow Medical Centre  
Nairobi  
Kenya

### Afarin Rahimi-Movaghar

Iranian National Center for Addiction Studies  
Tehran University of Medical Sciences  
Tehran  
Iran

### Rajat Ray

Chief  
National Drug Dependence Treatment Centre  
All India Institute of Medical Sciences  
New Delhi  
India

### Anthony J Smith

Emeritus Professor  
Clinical Pharmacology  
Newcastle Mater Hospital  
Australia

### Emilis Subata

Director  
Vilnius Center for Addictive Disorders  
Lithuania

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29336](https://www.yunbaogao.cn/report/index/report?reportId=5_29336)

